Pàgina inicial > Resultats de la cerca: Andre, Thierry
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 4 registres trobats en 0.01 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
11 p, 458.4 KB Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer / Yoshino, Takayuki (National Cancer Center Hospital East) ; André, Thierry (Sorbonne University) ; Kim, Tae Won (University of Ulsan) ; Yong, Wei Peng (National University Cancer Institute) ; Shiu, Kai-Keen (University College Hospital) ; Jensen, Benny Vittrup (Herlev and Gentofte Hospital) ; Jensen, Lars Henrik (University Hospital of Southern Denmark) ; Punt, Cornelis J. A. (University Medical Center Utrecht) ; Smith, Denis (Hôpital Haut-Lévêque) ; García-Carbonero, Rocío (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ; Alcaide-Garcia, Julia (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Gibbs, Peter (Western Hospital) ; de la Fouchardiere, Christelle (Centre Léon Bérard) ; Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Le, Dung T. (Johns Hopkins Medicine) ; Adachi, Noriaki (Merck (Estats Units d'Amèrica)) ; Fogelman, David (Merck(Estats Units d'Amèrica)) ; Marinello, Patricia (Merck (Estats Units d'Amèrica)) ; Diaz, Luis A. (Memorial Sloan Kettering Cancer Center) ; Universitat Autònoma de Barcelona
The phase 3 KEYNOTE-177 study evaluated pembrolizumab versus chemotherapy with or without bevacizumab or cetuximab in patients with newly diagnosed, microsatellite-instability-high (MSI-H)/mismatch-repair-deficient (dMMR) metastatic colorectal cancer (mCRC). [...]
2022 - 10.1111/cas.15650
Cancer Science, Vol. 114 (december 2022) , p. 1026-1036  
Registre complet - Creative Commons
2.
13 p, 1.6 MB Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers / Fucà, Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Cohen, Romain (Hôpital Saint-Antoine) ; Lonardi, Sara (Istituto Oncologico Veneto IOV-IRCSS) ; Shitara, Kohei (National Cancer Center Hospital East) ; Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Fakih, Marwan (City of Hope Comprehensive Cancer Center) ; Chao, Joseph (City of Hope Comprehensive Cancer Center) ; Klempner, Samuel J. (Harvard Medical School) ; Emmett, Matthew (Harvard Medical School) ; Jayachandran, Priya (University of Southern California) ; Bergamo, Francesca (Istituto Oncologico Veneto IOV-IRCSS) ; García, Marc Díez (Vall d'Hebron Institut d'Oncologia) ; Mazzoli, Giacomo (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Provenzano, Leonardo (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Colle, Raphael (Hôpital Saint-Antoine) ; Svrcek, Magali (Hôpital Saint-Antoine, AP-HP, and INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer) ; Ambrosini, Margherita (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Randon, Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Shah, Aakash Tushar (Baylor College of Medicine) ; Salati, Massimiliano (University Hospital of Modena) ; Fenocchio, Elisabetta (Candiolo Cancer Institute FPO-IRCCS) ; Salvatore, Lisa (Fondazione Policlinico Universitario Agostino Gemelli IRCCS) ; Chida, Keigo (National Cancer Center Hospital East) ; Kawazoe, Akihito (National Cancer Center Hospital East) ; Conca, Veronica (University of Pisa) ; Curigliano, Giuseppe (University of Milan) ; Corti, Francesca (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Cremolini, Chiara (University of Pisa) ; Overman, Michael (University of Texas MD Anderson Cancer Center) ; André, Thierry (Hôpital Saint-Antoine) ; Pietrantonio, Filippo (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Universitat Autònoma de Barcelona
Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of patients shows primary resistance or short-term disease control. [...]
2022 - 10.1136/jitc-2021-004001
Journal for immunotherapy of cancer, Vol. 10 (february 2022)  
Registre complet - Creative Commons
3.
6 p, 754.7 KB Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial / Auclin, Edouard (Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France) ; André, Thierry (Oncology Multidisciplinary Research Group (GERCOR)) ; Taieb, Julien (UMR-S 1147, INSERM) ; Banzi, Maria (Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy) ; Van Laethem, Jean-Luc (Université Libre de Bruxelles. Department of Gastroenterology and Digestive diseases, Hopital Erasme) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Hickish, Tamas (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ; de Gramont, Aimery (Institut Hospitalier Franco-Britannique. Department of Oncology) ; Vernerey, Dewi (Oncology Multidisciplinary Research Group (GERCOR)) ; Universitat Autònoma de Barcelona
Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2. 35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. [...]
2019 - 10.1038/s41416-019-0521-7
British Journal of Cancer, Vol. 121 (july 2019) , p. 312-317  
Registre complet - Creative Commons
4.
7 p, 242.6 KB Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : results from two randomized first-line panitumumab studies / Boeckx, N. (University Hospital Antwerp (Bèlgica)) ; Koukakis, R. (Biostatistics, Amgen Ltd) ; Op de Beeck, K. (University Hospital Antwerp (Bèlgica)) ; Rolfo, Christian (University Hospital Antwerp (Bèlgica)) ; Van Camp, G. (University Hospital Antwerp (Bèlgica)) ; Siena, S. (Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Douillard, Jean-Yves (Medical Oncology, Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France) ; André, Thierry (Department of Medical Oncology, Hôpital Saint Antoine; Sorbonne Universités, UMPC Paris 06 and GERCOR, Paris, France) ; Peeters, Marc (University Hospital Antwerp (Bèlgica))
Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. [...]
2017 - 10.1093/annonc/mdx119
Annals of oncology, Vol. 28 (april 2017) , p. 1862-1868  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
4 André, Thierry
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem